Drugs / selatinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01931943 | Apr → Dec 2013 | breast cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | selatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01931943 ↗ |
| Action | Inhibit | “an inhibitor of epidermal growth factor receptor (EGFR)” PMID 27902470 ↗ May 2017 |
| Route | Oral | “oral Selatinib Ditosilate Tablets” NCT01931943 ↗ |
| Target | EGFR | “an inhibitor of epidermal growth factor receptor (EGFR)” PMID 27902470 ↗ May 2017 |